Study of SCY-635, Pegasys and Copegus in Hepatitis C

Inclusion Criteria: * Quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL * Chronic HCV status * HCV genotype 1 infection and IL28B genotype of C/T or T/T * Liver biopsy results within 3 years prior to screening indicating the absence of cirrhosis \*If no previous biopsy is available, a biopsy must be performed during the screening period to qualify for randomization * Body mass index (BMI) between 18 and 38 kg/m2 * Laboratory variables within acceptable ranges: * ALT/AST \< 3 × ULN; * HgB \> 12g/dL for females, \> 13 g/dL for males; * total WBC count \> 3000/mm3 and ANC \> 1500/mm3; * platelets \> 100,000/mm3; * prothrombin time (or INR) ≤ 1.2 × ULN; * serum albumin ≥ 3.4 g/dL; * total bilirubin WNL; * serum creatinine WNL; if serum creatinine is \> ULN, then calculated creatinine clearance must be \> 100 mL/min (by Cockcroft-Gault formula) for subject to be eligible * Subjects of childbearing potential (i.e., not surgically sterile or postmenopausal) must agree to use 2 forms of contraception from Screening until 24 weeks after completion of treatment with RBV * Negative urine testing for amphetamines and cocaine at Screening. * If female, the subject has a negative pregnancy test at Screening and on study Day 1 Exclusion Criteria: * History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease * Females who are pregnant or breastfeeding * Males with partners who are pregnant or are planning to become pregnant * HCV genotype other than genotype 1 and an IL28B genotype of C/C * Seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg) * Use of any investigational agent within 3 months prior to dosing * Received any prior FDA-approved or investigational drug or drug regimen for the treatment of hepatitis C * Evidence of cirrhosis on a previous liver biopsy * Evidence of decompensated liver disease * Recipient of an organ transplant * Evidence of hepatocellular carcinoma * Evidence of ongoing alcohol or substance abuse * Poorly-controlled diabetes mellitus * Congestive heart failure or unstable cardiopulmonary condition, renal disease, or hemoglobinopathy (sickle cell anemia or thalassemia * History of seizure disorder * History of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or psychosis requiring medication * Concurrent medical condition or laboratory abnormality that would constitute a contra-indication for interferon use * History of unstable thyroid disease that would preclude administration of interferon-based therapy * Medical condition that requires use of systemic corticosteroids * Received warfarin or other anticoagulants during the 21 days immediately prior to Screening, or is expected to require warfarin or other anticoagulants during the study. * One or more additional known primary or secondary causes of liver disease, other than hepatitis C * Any other concurrent medical condition likely to preclude compliance with the schedule of evaluations, or likely to confound the efficacy or safety observations * 12-lead ECG showing the following: * Corrected QTc interval ≥ 450 msec (Bazett's correction); * QRS \> 120 msec; * Clinically significant abnormalities; * Severe retinopathy or other significant ophthalmological disorder * Use of any herbal supplements within 28 days prior to dosing. * The use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of treatment through Week 6